Spots Global Cancer Trial Database for second or third line
Every month we try and update this database with for second or third line cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | NCT00769067 | Non-small Cell ... | Erlotinib PF-00299804 | 18 Years - 99 Years | Pfizer | |
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | NCT00769067 | Non-small Cell ... | Erlotinib PF-00299804 | 18 Years - 99 Years | Pfizer | |
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | NCT00769067 | Non-small Cell ... | Erlotinib PF-00299804 | 18 Years - 99 Years | Pfizer |